Numerous studies have examined the willingness of physicians to communicate a terminal prognosis to a patient. The pattern of results suggests that there has been a shift from a widespread tendency not to tell patients of such a prognosis in the 1950s to a widespread tendency to tell in the 1980s. This paper reviews ten articles which document this apparent shift. In addition, this review reveals methodological, statistical, and theoretical shortcomings of the literature. These shortcomings seriously undermine the ability to use this literature as a basis for supporting what might otherwise be a reasonable claim concerning the shift in physicians' behavior. Hence, the present paper examines the nature of these shortcomings and makes suggestions for rectifying such problems in future research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07481188708253477 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.
Cardiovasc Diabetol
January 2025
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal LV morphology and function and/or abnormal cardiac biomarker concentrations.
Objective: To compare the evolution of four DbMD groups based on biomarkers alone, systolic and diastolic dysfunction alone, or their combination.
Effects of recombinant human growth hormone injection combined with Anastrozole on height and growth rate of adolescent idiopathic short stature and evaluation of adverse reactions.
Pak J Pharm Sci
January 2025
Department of Pediatrics, Changxing Peoples' Hospital Pediatrics, Huzhou, Zhejiang Province, China.
Recombinant human growth hormone (rhGH) injections combined with Anastrozole are increasingly used to treat adolescent idiopathic short stature (ISS), warranting further research. This study evaluated their effects on height, growth rate and adverse reactions in 72 adolescents with ISS treated at our hospital from December 2021 to December 2022. Patients were divided into a control group (rhGH alone) and a study group (rhGH + Anastrozole).
View Article and Find Full Text PDFMolecular Stratification of Light-Chain Cardiac Amyloidosis With F-Florbetapir and Ga-FAPI-04 for Enhanced Prognostic Precision.
JACC Cardiovasc Imaging
January 2025
Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Cardiac involvement in amyloid light chain (AL) amyloidosis significantly influences prognosis, necessitating timely diagnosis and meticulous risk stratification.
Objectives: This prospective study aimed to delineate the molecular phenotypes of AL cardiac amyloidosis (AL-CA) by characterizing fibro-amyloid deposition using F-florbetapir and gallium-68-labeled fibroblast activation protein inhibitor-04 (Ga-FAPI-04) positron emission tomography (PET)/computed tomography (CT) imaging. The authors also proposed a novel molecular stratification methodology for prognosis.
An innovative multicomponent compression system in a single bandage for venous leg ulcer and/or oedema treatment: a real-life study in 343 patients.
J Wound Care
January 2025
Department of Dermatology, Venereology, and Allergology of Katholisches Klinikum Bochum, Bochum, Germany.
Objective: This study aimed to evaluate the performance of an innovative multicomponent compression system in a single bandage (UrgoK1, Laboratoires Urgo, France) in the treatment of patients with venous leg ulcers (VLUs) and/or lower limb oedema in everyday practice.
Method: A prospective, observational, clinical study with the evaluated compression system was conducted in 39 centres in Germany between March 2022 and July 2023. Main outcomes included a description of the treated patients, changes in wound healing and oedema progression, local tolerance and acceptability of the compression system.
Comparative study on blood pressure and metabolic improvements in hypertensive patients using copper bianstone scraping.
Medicine (Baltimore)
January 2025
Nephrology Department, Changzhou Traditional Chinese Medicine Hospital, Changzhou City, China.
To evaluate the effectiveness and feasibility of the copper bianstone scraping combined with Chinese modified termination hypertension dietary therapy program by comparing and analyzing the improvement of blood pressure, blood lipids and blood glucose in hypertensive patients who received copper bianstone scraping combined with Chinese modified termination hypertension dietary therapy intervention. We selected 160 cases of hypertensive patients from July 2022 to March 2024 for the study. They were divided into 80 cases in the comparison group and 80 cases in the observation group according to whether or not they underwent copper bianstone scraping combined with Chinese modified dietary therapy for termination of hypertension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!